Brief: Xbrane Provides Update On Ranibizumab Biosimilar Candidate FDA Filing

Xbrane Biopharma AB

30/05/2022 07:05

May 30 (Reuters) - Xbrane Biopharma AB  XBRANE.ST :
    * XBRANE PROVIDES UPDATE ON RANIBIZUMAB BIOSIMILAR CANDIDATE
FDA
FILING
    * HAS WITHDRAWN BIOLOGICS LICENSE APPLICATION FOR ITS
INVESTIGATIONAL BIOSIMILAR CANDIDATE TO LUCENTIS AFTER RECEIVING
FEEDBACK FROM FDA
    * WILL RECEIVE MORE INFORMATION ABOUT REQUESTED
COMPLEMENTARY
INFORMATION FROM FDA IN A FEW WEEKS
    * AFTER RECEIVING INFORMATION FROM FDA, FIRM TIMELINE FOR
RE-SUBMISSION OF BLA WILL BE COMMUNICATED

Source text for Eikon:  ID:nMFN5Bdvhm 
Further company coverage:  XBRANE.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))